Ana Domingos, PhD

November 03, 2020

The Domingos laboratory researches neuroimmune mechanisms underlying obesity. They discovered neuro-adipose junctions, between white adipocytes and sympathetic neurons, that are necessary and sufficient for fat mass reduction via norepinephrine (NE) signalling. Moreover, they discovered Sympathetic neuron-Associated Macrophages (SAMs) that import and metabolize NE. Abrogation of SAM function promotes long-term amelioration of obesity independently of food intake. These findings inspired the development of a new class of anti-obesity compounds named sympathofacilitators, which do not enter the brain, nor have the typical cardiovascular side effects of centrally acting sympathomimetic drugs.  Sympathofacilitator drugs act as an energy sink by coupling thermogenesis to active heat dissipation. Ana Domingos is a member of the advisory board of Cell Metabolism and her lab has been funded by HHMI, Wellcome Trust, ERC, HFSP, EMBO among others.

 

Last Updated:
Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!